Madrigal Pharmaceuticals overview

Madrigal Pharmaceuticals (MDGL) has been drawing closer attention after recent trading, with the stock closing at US$511.89 and showing mixed return patterns over the past year and past 3 months.

The 18.27% 1 month share price return contrasts with a 13.80% share price decline year to date. The 1 year total shareholder return of 69.06% points to stronger longer term momentum.

If you are weighing Madrigal against other high growth stories, this could be a useful moment to see what else is on the move through 37 healthcare AI stocks

With Madrigal now valued at about US$12.2b and trading at a discount to the US$668.57 analyst price target, the key question is whether the recent gains leave upside on the table or if markets are already pricing in future growth.

Most Popular Narrative: 23.7% Undervalued

Compared with the narrative fair value of $671.07, Madrigal’s last close at $511.89 leaves a sizeable valuation gap that the most followed thesis tries to explain.

The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity. This increases the likelihood of sustained top-line growth and supports margin expansion due to extended pricing power.

Want to see what kind of revenue curve and margin shift sit behind that fair value? The narrative leans on aggressive expansion, richer profitability, and a premium future earnings multiple.

Result: Fair Value of $671.07 (UNDERVALUED)

However, you still need to weigh risks such as heavy reliance on Rezdiffra, as well as potential pricing or market share pressure if GLP 1 competitors gain traction.

Next Steps

With sentiment clearly mixed in this story, it helps to look at the full picture yourself and decide where you stand. You can start with the 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Madrigal has your attention, do not stop here. Put the same focus into finding other opportunities that fit your style and risk comfort.

• Target resilient balance sheets and steady fundamentals by scanning the solid balance sheet and fundamentals stocks screener (40 results).
• Spot potential value opportunities before others by reviewing the 61 high quality undervalued stocks.
• Hunt for lesser known names with strong qualities using the screener containing 24 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.